

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/525,951
Filing Date	February 28, 2005
First Named Inventor	SHABAT Doron et al
Art Unit	1611
Examiner Name	LOVE, TREVOR M
Attorney Docket Number	29195

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. †	Foreign Patent Documents	Publication Date DD-MMM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code* Number* Kind Code* (if known)			
T/L	1	WO 01/87348	22-Nov-2001	Baker et al.	
	2	WO WO 98/13059	02-Apr-1998	Firestone	
T/L	3	WO 98/19705	14-May-1998	King et al.	
Examiner Signature	/Trevor Love/			Date Considered	08/14/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard SI-3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is requested to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application forms to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substituted for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known Application Number 10/525,951 Filing Date February 28, 2005 First Named Inventor SHABAT Doron et al Group Art Unit 1611 Examiner Name LOVE, TREVOR M Attorney Docket Number 29195	
Sheet	2	Of	2		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
	4	International Search Report Dated 13 January 2004 From the International Searching Authority Re.: Application No. PCT/IL03/00711.			
	5	Antczak et al. "A New Acivicin Prodrug Designed for Tumor-Targeted Delivery", Bioorganic & Medicinal Chemistry, XP001150714, 9: 2843-2848, 2001. Abstract, Scheme 1.			
	6	De Groot et al. "Elongated Multiple Electronic Cascade and Cyclization Spacer Systems in Activatable Anticancer Prodrugs for Enhanced Drug Release", Journal of Organic Chemistry, XP002212035, 66: 8815-8830, 2001. Abstract, P.8823, r-h Col., 4th §, P.8824, l-h Col., 4th §, Schemes 1, 5-7, Figs.2, 4.			
	7	De Groot et al. "Synthesis and Biological Evaluation of 2'-Carbamate-Linked and 2'-Carbonate-Linked Prodrugs of Paclitaxel: Selective Activation by the Tumor-Associated Protease Plasmin", Journal of Medicinal Chemistry, XP002212034, 43: 3093-3102, 2000. Abstract, Chart 1, Scheme 1.			
	8	Niculescu-Duvaz et al. "Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy", Journal of Medicinal Chemistry, XP002265049, 41(26): 5297-5309, 17 December 1998. Abstract, Scheme 1, Table 1.			
	9	Toki et al. "Protease-Mediated Fragmentation of ?-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs", Journal of Organic Chemistry, XP002265050, 67(6): 1866-1872, 22 March 2002. Abstract, Schemes 1-5, Table 1, Fig.1.			
Examiner Signature	/Trevor Love/			Date Considered	08/14/2009

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*